嵌合抗原受体-T细胞治疗时代多参数流式细胞术临床应用的机遇与挑战

Opportunities and challenges for the clinical application of multi-parameter flow cytometry in the era of chimeric antigen receptor-modified T cell immunotherapy

嵌合抗原受体(CAR)-T细胞免疫治疗已成为肿瘤领域新的免疫治疗明星治疗技术,2017年至今已经有5款CAR-T细胞产品获批上市。CAR-T细胞免疫治疗的基础研究与临床实践良性、快速、高效的互动也发现并解决了很多新的科学问题,大大拓展了多参数流式细胞术(MFC)的应用领域。MFC贯穿了CAR-T细胞制备、改进和功能评价、质量控制、体内存续、临床疗效和毒副作用评估监测全过程。CAR-T细胞高精度的靶向治疗所带来的新的临床问题,对流式细胞术从业人员采用MFC进行肿瘤准确免疫分型和微小残留病监测提出新的挑战,同时也提出了不同疾病阶段,全面评估机体精细免疫功能状态的需求。靶向治疗时代,实验室和临床的及时沟通交流,对于获取正确MFC检测结果、辅助临床个体化诊疗尤为重要。

Chimeric Antigen Receptor-modified(CAR)-T cells have become a new star living cell"drug"in the field of tumor immunotherapy,and five drugs have been available to the public since 2017.The favourable,rapid and efficient interaction of CAR-T therapy from bench to bedside has solved many new scientific problems,which remarkably expands the application field of multi-parameter flow cytometry(MFC).MFC participates the whole process of CAR-T preparation,functional evaluation,quality control,in vivo continuation evaluation,clinical efficacy and toxicity monitoring.New clinical problems caused by high-precision targeted therapy of CAR-T cells pose new challenges in using MFC for accurate tumor immunophenotyping,minimal residual disease monitoring,as well as the demands of comprehensively evaluation of the systematic immune function in different disease stages.In the era of targeted therapy,timely communication between laboratories and clinics is particularly important for obtaining accurate MFC results,which assists clinical individualized diagnosis and treatment.